NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE141958 Query DataSets for GSE141958
Status Public on Dec 13, 2019
Title Genome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients
Organism Homo sapiens
Experiment type Expression profiling by array
Summary The iron chelator deferasirox is widely used in patients with iron overload. Patients with low-grade myelodysplastic syndromes (MDS) get transfusion dependency and need to be treated with deferasirox to avoid iron overload. Moreover, in some patients an increase in both erythroid and platelets have been observed after deferasirox therapy. However, the mechanisms involved in these clinical findings are poorly understood. The aim of this work was to analyze, in patients treated with deferasirox, the changes in the gene expression profile after receiving the treatment. A total of fifteen patients with the diagnosis of low-grade MDS were studied. Microarrays were carried out in RNA from peripheral blood before and after 14 weeks of deferasirox therapy. Changes in 1,457 genes and 54 miRNAs were observed: deferasirox induced the downregulation of genes related to the Nf kB pathway leading of an overall inactivation of this pathway. In addition, the iron chelator also downregulated gamma interferon. Altogether these changes could be related to the improvement of erythroid response observed in these patients after therapy. Moreover, the inhibition of NFE2L2/ NRF2, which was predicted in silico, could be playing a critical role in the reduction of reactive oxygen species (ROS). Of note, miR-125b, overexpressed after deferasirox treatment, could be involved in the reduced inflammation and increased hematopoiesis observed in the patients after treatment. In summary this study shows, for the first time, the mechanisms that could be governing deferasirox impact in vivo.
 
Overall design Paired analysis of low risk MDS treated with deferasirox.
 
Contributor(s) Hernández Sánchez JM, Rodríguez Vicente AE
Citation(s) 32015457
Submission date Dec 12, 2019
Last update date Mar 17, 2020
Contact name Jesus Maria Hernandez Sanchez
E-mail(s) jesus807@gmail.com
Phone 659124128
Organization name Cancer Research of Salamanca
Lab Oncohematology
Street address Av Coimbra S/N
City Salamanca
State/province España
ZIP/Postal code 37007
Country Spain
 
Platforms (1)
GPL17586 [HTA-2_0] Affymetrix Human Transcriptome Array 2.0 [transcript (gene) version]
Samples (30)
GSM4217074 1_Pre-Deferasirox
GSM4217075 1_Post-Deferasirox
GSM4217076 2_Pre-Deferasirox
Relations
BioProject PRJNA595388

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE141958_RAW.tar 670.4 Mb (http)(custom) TAR (of CEL)
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap